BMJ · 12 Nov 2026
Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial
Weiqing Wang, Yu Xu, Fengmei Xu, Huanfeng Pan, Xiuqin Geng, Yufang Li, Yifei He, Guihong Xing, Jieli Lu, Tiange Wang, Yan Liu, Tingzhi Li, Peng Duan, Qian Zhang, Jiangmin Wang, Yonghui Zhao, Ping Lu, Ruizhi Zheng, Yuhong Chen, Songbo Fu, Shengli Wu, Weihong Chen, Hongting Zheng, Juan Deng, Shengdi Chen, Jun Liu, Binyin Li, Weiguo Hu, Shujing Wu, Jingya Niu, Jingya Wang, Qi Zhou, Leshan Liu, Xiaolu Wang, Yusen Zhou, Dekuan Liu, Qiuyun Li, Deyu Shang, Airong Zheng, Chunfang Zhang, Yuchen Xu, Jiqiu Wang, Xiadi He, Siyu Wang, Zhihong Wang, Guoyue Yuan, Jijun Peng, Peixia Cui, Suijun Wang, Hongbo Dang, Fuhua Yan, Naying He, Qin Wan, Jian Yang, Yu Liu, Guang Ning, Mian Li, Yufang Bih-index 18
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Objective To evaluate the effect of intensive compared with standard treatment of systolic blood pressure (SBP) on cognitive outcomes and brain structures in adults with type 2 diabetes. Design Multicentre, open label, outcome assessor masked, randomised controlled trial. Setting 145 clinical centres across seven geographical regions in China. Participants 12 821 adults aged ≥50 years with type 2 diabetes, raised SBP, and increased cardiovascular risk, of whom 12 434 without probable dementia at baseline were included in this cognitive ancillary study. Further assessments were performed annually and at the end of study. Interventions Participants were randomly assigned to receive intensive treatment targeting SBP <120 mm Hg or standard treatment targeting SBP <140 mm Hg for up to five years. Main outcome measures The primary cognitive outcome was a composite of all cause dementia or mild cognitive impairment. Secondary cognitive outcomes included all cause dementia, mild cognitive impairment, changes in cognitive functions, and changes in brain magnetic resonance imaging (MRI) characteristics. A subset of participants underwent brain MRI at baseline (n=862) and at the end of study (n=605) to assess changes in white matter lesion volume and total brain volume. Results 6219 participants were assigned to receive intensive treatment and 6215 to receive standard treatment. Baseline mean age was 63.7 years, and 5567 (44.8%) participants were women. After one year, mean SBP was 121.6 mm Hg in the intensive treatment group and 133.2 mm Hg in the standard treatment group. During a median follow-up of 3.8 years, the primary cognitive outcome of all cause dementia or mild cognitive impairment occurred in 747 participants (3.69 events per 100 person years) in the intensive treatment group and 783 participants (3.89 events per 100 person years) in the standard treatment group (hazard ratio 0.96, 95% confidence interval (CI) 0.86 to 1.06; P=0.38). In the MRI substudy (428 intensive treatment v 434 standard treatment), the intensive treatment group had a smaller increase in white matter lesion volume compared with the standard treatment group (between group difference −0.09 inverse hyperbolic sine (asinh) transformed cm 3 , 95% CI −0.15 to −0.02; P=0.01). Conclusions Over a median of about four years, no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP (target <140 mm Hg) and intensive treatment (target <120 mm Hg). Intensive treatment was, however, associated with a reduction in the accrual of cerebral white matter lesion volume. Trial registration ClinicalTrials.gov NCT03808311 .
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Yufang Bi has the highest h-index among the authors (18).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (36)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 16 more references
A free account opens the rest of the citing papers and references on every paper’s page.